Summary This article reports a taxonomic classification of rare skeletal diseases based on metabolic phenotypes. It was prepared by The Skeletal Rare Diseases Working Group of the International Osteoporosis Foundation (IOF) and includes 116 OMIM phenotypes with 86 affected genes. Introduction Rare skeletal metabolic diseases comprise a group of diseases commonly associated with severe clinical consequences. In recent years, the description of the clinical phenotypes and radiographic features of several genetic bone disorders was paralleled by the discovery of key molecular pathways involved in the regulation of bone and mineral metabolism. Including this information in the description and classification of rare skeletal diseases may improve the recognition and management of affected patients. Methods IOF recognized this need and formed a Skeletal Rare Diseases Working Group (SRD-WG) of basic and clinical scientists who developed a taxonomy of rare skeletal diseases based on their metabolic pathogenesis.
Introduction
A disease or disorder is defined as rare or Borphan^when it affects less than 5 in 10,000 individuals or has a prevalence of <7.5/100,000 [1] [2] [3] . More than 6000 rare disorders have been described affecting approximately 30 million individuals in the USA and 27-36 million in the EU [1, 4-6; http://www. fda.gov/; http://ec.europa.eu/research/fp7/index_en.cfm; http://www.ema.europa.eu/pdfs/human/comp/29007207en. pdf), with almost half affecting children [7] . Many of these conditions are complex, severe, degenerative, and chronically debilitating [1, 7] , and there is a need for recognition, diagnosis, and treatment of affected individuals. Due to the rarity of these disorders, international cooperation and coordination of research and funding are essential [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .
Genetic disorders involving primarily the skeletal system represent a considerable portion of the recognized rare diseases, and more than 400 different forms of skeletal dysplasia have been described [19] . Accumulating evidence of the clinical and genetic heterogeneity of skeletal disorders has led to different classifications of these disorders based on their clinical and radiological features and, subsequently, their molecular and embryological features [20] [21] [22] [23] [24] . In 2011, Warman et al. [25] proposed a classification of rare skeletal disorders based on four criteria: (1) significant skeletal involvement, corresponding to the definition of skeletal dysplasia, metabolic bone disorders, dysostoses, and skeletal malformation and/or reduction syndromes; (2) publication and/or listing in MIM (meaning that observations should not find their way into the nosology before they achieve peer-reviewed publication status); (3) genetic basis proven by pedigree or very likely based on homogeneity of phenotype in unrelated families; and (4) nosology au- Fig. 2 The bone metabolic machinery tonomy confirmed by molecular or linkage analysis and/ or by the presence of distinctive diagnostic features and of observation in multiple individuals or families. Using these criteria, the authors identified 456 different conditions which they classified in 40 groups. Of these conditions, 316 were associated with one or more of 226 different gene defects [25, 26] . Nowadays, several websites, mainly focusing on genetics, are available ( Fig. 1 ) and can be used as reference once a rare disease is identified.
Bones are formed during embryonic development through two major mechanisms: endochondral and intramembranous ossification. This process, called modeling, begins in utero and continues throughout adolescence until skeletal maturity. Following skeletal maturity, bone continues to be broken down and rebuilt (remodeling) throughout life and adapts its material to the mechanical demands. Remodeling has the function of the control of mineral homeostasis and of maintaining the biomechanical competence of the skeleton. The Fig. 3 Osteoclasts (OCs), the bone-resorbing cells, are multinucleated cells originating from precursor cells derived from the mononuclear myeloid lineage, which also give rise to macrophages [42] . The main regulators of osteoclastogenesis are cells of the osteoblastic lineage, through the release in the bone microenvironment of important chemokines, as macrophage-colony stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), both active on the OC precursors (OCPs) [42] . M-CSF binds to its receptor, c-fms, on OCPs and activates signaling through MAP kinases and ERKs during the early phase of OCP differentiation [43] . RANKL binds to its receptor, RANK, on the surface of OCPs, activating signaling through NF-κB, c-Fos, phospholipase Cγ (PLCγ), and nuclear factor of activated T cells c1 (NFATc1), to induce differentiation of OCPs into mature osteoclasts [44] . Osteoprotegerin (OPG), also secreted by osteoblasts in response to several local and systemic factors, functions as a decoy receptor that binds RANKL and prevents it from interacting with RANK, limiting OC formation, activity, and survival [45] . In pathological conditions, remodeling/modeling activity can be increased or decreased. The bone resorption process is complex; two phases in this pathway can be recognized, namely acid secretion and proteolysis [46] . The model of bone degradation clearly depends on physical intimacy between the osteoclast and bone matrix, a role provided by integrins. Integrins, alpha beta (ανβ3) heterodimers, are the principal cell matrix attachment molecules and they mediate osteoclastic bone recognition creating a sealing zone, into which hydrochloric acid and acidic proteases such as cathepsin K are secreted [47] . Acid secretion is initiated through the active secretion of protons through a vacuolar type ATPase (V-ATPase) and passive transport of chloride through a chloride channel [48, 49] , with a final dissolution of the inorganic bone matrix [50] . Acid production is accompanied by an increased chloride transport [46, [51] [52] [53] [54] [55] and the involvement of the enzyme carbonic anhydrase II (CAII), which catalyzes conversion of CO 2 and H 2 O into H 2 CO 3 , thereby providing the protons for the V-ATPase [56] . Proteolysis of the type I collagen matrix in bones is mainly mediated by the cysteine proteinase, cathepsin K, which is active at low pH in the resorption lacunae [46, 50, 57, 58] . Products of bone metabolism can be measured, with fragments of collagen type I being the most direct indicators of the osteoclastic activity [59] [60] [61] components of the metabolic bone tissue machinery are depicted in Fig. 2 . The cells involved in the metabolic activity of the skeleton are osteoclasts (OCs), osteoblasts (OBs), and osteocytes [27] . The bone extracellular matrix (ECM), known as osteoid, is a complex of self-assembled macromolecules composed predominantly of collagens (~90 % of the matrix proteins), noncollagenous glycoproteins, hyaluronan, and proteoglycans. The osteoid and its local modulating factors are also primary factors in the metabolic performance of bone tissue. The mineral is another important component of the metabolic machinery of bone tissue. The metabolic activity of bone is controlled by systemic and local factors and mechanical signals depicted in Figs. 3, 4, 5, 6 , and 7 [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] .
The major advances in our understanding of the regulation of bone metabolism in recent years allow a different approach to the classification of rare skeletal diseases based on their metabolic pathogenesis. Such approach cannot only improve the recognition and diagnosis of affected patients but can also lead to identification of new targets for therapeutic interventions. In addition, it can Fig. 4 Osteoblasts (OBs) are bone-forming cells that originate from mesenchymal stem cells (MSCs). The complexities of bone formation are immediately apparent in the embryo, where different regions of the skeleton arise either from intramembranous bone formation or from the endochondral sequence. Osteogenesis is regulated by many molecules, including transcription factors, growth factors, cytokines, and hormones, acting through paracrine, autocrine, and endocrine mechanisms [27] , with axial and appendicular-derived osteoblasts exhibiting different responses to hormones [24, 62, 63] . Factors critical in osteoblastogenesis and in mature OBs function are represented by Runx2, Osterix, Wingless (Wnt), lipoprotein receptor-related protein 5 and 6 (Lrp5/6), and bone morphogenetic proteins (BMPs) [27] . OBs are responsible for the deposition of bone extracellular matrix (osteoid), which become mineralized, by deposition of calcium hydroxyapatite, giving the bone rigidity and strength. Biomineralization is characterized by development of matrix extracellular vesicles that are formed by polarized budding from the surface membrane of OBs [64] . The mineralization begins with the formation of hydroxyapatite crystals [calcium (Ca) and inorganic phosphate (Pi)] within matrix vesicles. Ca is incorporated in vesicles by annexin Ca channel, Ca-binding phospholipids calbindins and sialoprotein. Pi is provided by type III Na/Pi cotransporter, by PHOSPHO1, and from the activity of tissue-nonspecific alkaline phosphatase that hydrolyzes pyrophosphate (PPi) [64] . This process is followed by propagation of hydroxyapatite through the membrane into the extracellular matrix in clusters around matrix vesicles and fills the space between collagen fibrils in the skeletal matrices. PPi inhibits the formation of hydroxyapatite. The ratio of Pi to PPi that is mediated by alkaline phosphatase activity is crucial in this step of mineralization [64] . Markers of bone formation are measurable, some being enzymes or proteins produced by osteoblasts (i.e., alkaline phosphatase and osteocalcin) [60, [65] [66] [67] [68] [69] , while others derive from type I collagen metabolism (i.e., procollagen type I propetides) [60] provide bone specialists the background for the diagnostic evaluation of biochemical alterations in individual patients and can contribute to their better understanding of the etiology of the disease.
The aim of the present article, resulted from the work of the members of the Skeletal Rare Diseases Working Group (SRD-WG) of the International Osteoporosis Foundation (IOF), is to classify rare skeletal disorders according to alterations of specific genes encoding proteins involved in the activity of bone cells, bone matrix proteins, microenvironmental regulators essential for bone physiology, or response to calciotropic hormones. In the adult skeleton, osteocytes make up 90−95 % in volume of all bone cells compared with 4-6 % osteoblasts and 1-2 % osteoclasts [70] . Osteocytes establish an extensive intercellular communication system via gap-junction-coupled cell processes, also extended to OBs and OCs on the bone surface and, therefore, represent an ideal mechanosensory system. Various authors have identified several transitional stages between osteoblasts and osteocytes. In their review article, Franz-Odendaal et al. [71] combined these observations to propose eight recognizable transitional stages from the osteoblast to the osteocyte. These authors favor an embedding mechanism in which a subpopulation of osteoblasts on the bone surface slows down matrix production relative to adjacent cells and becomes Bburied alive^under the matrix produced by neighboring osteoblasts. Sclerostin, the SOST gene protein product, is specifically expressed in osteocytes and inhibits osteoblast function and bone formation by antagonizing canonical Wnt signaling through binding to Wnt coreceptor Lrp5 and Lrp6, with Sost-deficient mice being resistant to bone loss at unloading [72] . In addition, Dickkopf (in particular Dkk-1) protein, expressed in many cell types, is highly expressed in osteocytes [73] and has also been shown to bind to Lrp5/6 and a transmembrane protein, Kremen, inhibiting canonical Wnt activation pathway [74] . The function of osteocytes in bone formation is still a matter of debate. Under in vitro application of mechanical stimuli, osteocytes activate bone formation through the release of anabolic factors [i.e., prostaglandin E2 (PGE2), prostaglandin I2 (PGI2), nitric oxide (NO), cyclooxygenase-2 (COX-2), and endothelial nitric oxide synthase (eNOS)] [72] , with bone formation being severely inhibited after osteocyte ablation [75] . Within the past two decades, several markers of osteocytes have been identified [74, 76, 77] . It is known that there is a heterogeneity in gene expression in osteocytes within bone. For example, early embedding osteoid osteocytes and young osteocytes express high levels of E11/gp38 (also known as podoplanin), while more mature, deeply embedded osteocytes express high levels of sclerostin [78] . Moreover, several proteins that are osteocyte specific, or selectively expressed in osteocytes, play critical roles in phosphate homeostasis. These include phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX), matrix extracellular phosphoglycoprotein (MEPE), dentin matrix protein 1 (DMP1), and fibroblast growth factor 23 (FGF23) [79] . Compared to OBs, osteocytes also appear to be enriched in proteins associated with resistance to hypoxia [80] due to their embedded location within bone, as expected [79] . Another important category of factors whose expression is different in osteocytes compared to OBs is molecules involved in cytoskeletal function and cell motility (destrin, CapG, cdc42, and E11/gp38) [79, 80] 
Material and methods
In 2012, the IOF recognized the need for identifying and managing patients with rare skeletal diseases and established a working group (SRD-WG) of experts in diseases of bone metabolism to address this issue. The members of the group, after reviewing existing literature information and consulting other physicians involved in the management of patients with rare skeletal diseases, concluded that classification of these diseases according to their metabolic pathogenesis was more appropriate and prepared the first draft of the manuscript. The criteria used to include different disorders were as follows: skeletal involvement as linked to major alterations of bone metabolism, publication and/or listing in the Online Mendelian Inheritance in Man (OMIM) system, and nosologic autonomy (literature updated with PubMed database searches up to January 2015). The SRD-WG considered abnormalities of all elements known to influence bone metabolism and included disorders that are rare, metabolic, and skeletal in origin whose genetic basis is proven or suspected on the basis of the phenotype. This classification does not, therefore, include skeletal dysplasias due to altered morphogenesis during embryonic development. In addition, we did not include in the classification rare diseases in which alterations in the actors of bone metabolism are not the primary cause of the syndrome and bone is only secondarily involved (e.g., storage disorders). This manuscript is the result of several discussions and revisions of the original draft and represents the consensus reached by the members of the group. Acronyms for the disorders described, phenotype, and gene/locus numbers are presented according to the nomenclature of the OMIM database, as most recently accessed in January 2015 (http://www.ncbi.nlm.nih.gov/ omim). An OMIM entry preceded by a number sign (#) indicates the phenotype and specific OMIM entries for the genes/loci whose mutations have been shown as responsible for that phenotype (http://web.udl.es/dept/ Fig. 6 Bone ECM is not only a scaffold for the cells, but also serves as a reservoir for growth factors and cytokines, and modulates bone turnover and mineral deposition [81, 82] . Type I collagen, synthesized by the OBs, is the most abundant extracellular protein of bone tissue (85-90 %), being essential for bone strength. The molecules of mature collagen spontaneously assemble into fibrils, and cross links form to increase the tensile strength of the fibrils [83] . Different cytokines, inflammatory mediators, matrix-degrading enzymes, hormones, and growth factors can modify the synthesis and degradation of type I collagen, within well-orchestrated autocrine and paracrine anabolic and catabolic pathways [81] [82] [83] . Noncollagenous proteins (NCPs) compose 10-15 % of the total bone protein content. These proteins are multifunctional, having roles in organizing the extracellular matrix, coordinating cell-matrix and mineral-matrix interaction, and regulating the mineralization process. [82] . The NCP molecules can be classified into four groups: (1) proteoglycans, (2) glycosylated proteins, (3) glycosylated proteins with potential cell adhesion properties, and (4) γ-carboxylated (gla) proteins [28, [82] [83] [84] [85] . Since mutations in these proteins cause mainly skeletal dysplasia, they have not been considered in the proposed classification cmb/biomatica/OMIM.PDF). The names of genes/loci are those approved by HGNC (HUGO Gene Nomenclature Committee, http://www.genenames.org). Diseases for which the OMIM classification leads to a confounding numbering system (e.g., osteogenesis imperfecta) have been listed into grouping in phenotypes according recently to suggested taxonomies. Diseases for which a specific OMIM phenotype has been described, but for which the genetic alteration has not yet been detected (e.g., Gorham-Stout disease), have in any case been included in the tables. For diseases for which locus heterogeneity has been recognized (e.g., Camurati-Engelmann disease), the main genetic alteration has been herein reported. A brief description of the phenotype and altered biomarkers, when available, has been reported for each rare metabolic bone disease, in order to focus on the metabolic phenotype, even for cases for which this latter information is indicated as BNR^(not reported). In Fig. 8 , the available nondisease-specific screening/diagnostic assays, which could be of use to further refine the diagnosis, have been listed.
Some diseases/phenotypes overlap in two or more tables because of multiple alterations in bone metabolism (e.g., a pure osteoblast defect can manifest into a disorder of bone matrix). Following a metabolic-based taxonomy, these specific disorders have to be indicated in more than one table. Thus, a disease resembling a phenotype due, for example, to an alteration of collagen metabolism, but due to a primitive alteration in osteoblast (e.g., osteogenesis imperfecta type IV due to mutations of SP7 or PLS3) has been primarily inserted in Tables 1, 2 , 3, and 4, encompassing the alterations in osteoblasts, which indeed ultimately lead to collagen metabolism alteration, and secondarily in Tables 5 and 6 , since they resemble a disorder in bone matrix (and referred to as Bsee Tables 1,  2 , 3, and 4^).
Results
Rare genetic metabolic bone disorders (RGMBDs) were classified in four major groups according to their primary pathogenetic mechanism: altered osteoblast, osteoclast, or osteocyte function; altered bone matrix proteins; altered bone microenvironmental regulators; and altered calciotropic hormonal activity. We report 116 diseaserelated OMIM phenotypes with 86 affected genes, and we include genetic causes (germ line mutations, postzygotic somatic mutations, mitochondrial DNA) where known, as well as general and bone-specific features and biochemical alterations.
Altered osteoblast, osteoclast, or osteocyte function Tables 1, 2 , 3, and 4 describe diseases due to an alteration in the activity of bone cells (osteoclasts, osteoblasts, and osteocytes) resulting in an increase or decrease in either bone formation or bone resorption. The four main groups identified include 38 different phenotypes. Disorders characterized by high bone resorption are shown in Table 1 , while those associated with low bone resorption are shown in Table 2 . These disorders are generally caused by mutations in genes encoding osteoclastic functional proteins. Table 3 depicts disorders characterized by high bone formation. These are caused by mutations in genes encoding proteins involved in osteoblastogenesis and mature osteoblast function or proteins produced by osteocytes involved in differentiation and life span of osteoblasts. Finally, diseases characterized by low bone formation are shown in Table 4 ; these are caused by mutations in genes encoding proteins involved in the formation and function of osteoblasts. Tables 5 and 6 describe diseases where the characteristics of matrix proteins are altered. Three major groups were identified, with 28 different phenotypes (five overlapping with the forms listed in Tables 1, 2 , 3, and 4). Regarding the diseases related to proteoglycan alterations, only the forms where the large proteoglycans are involved in the pathogenesis were included. Mutations in genes encoding type I collagen and collagen-related bone matrix proteins have been primarily listed in rare skeletal disorders characterized by altered collagen metabolism (Table 5 ). Alkaline phosphatase is one of the main enzymes involved in bone mineralization. Disorders causing altered production of alkaline phosphatase have been described primarily in Table 6 . Tables 7, 8 , 9, and 10 depict diseases caused by mutation of genes encoding for proteins involved in the regulation of bone turnover. Four major groups were recognized with 13 different phenotypes (12 overlapping with the forms listed in Tables 1,  2 , 3, and 4 or 5 and 6). Tables 11, 12 , 13, and 14 describe diseases with bone involvement due to congenital alterations of the function of hormones involved in the regulation of calciotropic hormones. Four major groups were described with 54 different phenotypes. Disorders due to parathyroid hormone excess or deficiency are listed in Table 11 , while diseases caused by altered parathyroid hormone (PTH) signaling and abnormal vitamin D metabolism and action are shown in Tables 12 and 13, respectively.  Table 14 displays disorders due to altered phosphate metabolism.
Altered bone matrix proteins

Altered bone microenvironmental regulators
Altered calciotropic hormonal activity
Discussion
We propose here for the first time a classification system for rare skeletal bone diseases based on a metabolic approach, selecting from this large number of disorders those due to an abnormality of the actors of bone metabolism: bone cells, bone matrix, and local and systemic regulators. The primary aim of this taxonomy is to provide a reference list on a metabolic basis, and only secondarily to help in the diagnostic workup. For this reason, the information regarding family history, genetic evaluation, and management of the different disorders reported was not included in the classification. We acknowledge further that this classification is arbitrary, but it has the strength that is based on actual, known findings that will encourage clinicians to perform proper metabolic evaluation of patients in order to plan targeted suitable treatment. It should be also noted that some level of arbitrary judgment is always compatible with a taxonomy process, and the same criticism can be posed toward a radiological classification that does not encompass information that we consider relevant for the clinical management of such difficult patients. In addition, such evaluation can be of clinical relevance in targeting appropriate treatment, when available, that generally is not timely and appropriately prescribed in the majority of patients. Finally, this metabolic taxonomy does not undermine the importance of previous classifications on this subject, which still constitute a reference list for these disorders [25] .
To date, the diagnosis of rare skeletal diseases is based on clinical phenotype and radiographic features. A classification system based on measurement of bone mineral density (BMD) or assessment of skeletal fragility is not feasible because in the majority of these disorders, systematic evaluation of BMD by DXA has not yet been performed, and the long-term incidence of fracture is unknown. Classification of Blocal^or Bsystemic^disorders is also not feasible, because in apparently localized disorders, a systemic alteration in Fig. 7 Calciotropic hormones are defined on the basis of their capability to modulate Ca/Pi metabolism, and all of them directly and indirectly modulate bone metabolism. Ca and Pi are essential to many vital physiological processes [29] and their regulation involves a concerted action among the digestive system, kidneys, and skeleton via the action of calciotropic hormones. Disturbances in calciotropic hormone homeostasis have been linked to several pathophysiological disorders, including bone abnormalities [29, 30] . Among the hormones that control Ca and Pi metabolism, parathyroid hormone (PTH) and calcitriol [1-25(OH) 2 D 3 ] are the most documented. PTH inhibits renal Pi reabsorption and increases Ca reabsorption, indirectly increasing intestinal Ca and Pi absorption by stimulating the synthesis of calcitriol. Conversely, Ca and Pi modulate the synthesis and secretion of PTH from parathyroid cells [31] . Homeostasis of calcium is represented in a. The symbol orange + indicates the direct PTH stimuli and orange (+) indicates the PATH indirect stimuli. The symbol blue + indicates the vitamin D stimuli. Parathyroid cells respond to decreases in extracellular calcium concentration by means of the calcium-sensing receptor (CaSR), a cell surface receptor that alters phosphatidylinositol turnover and intracellular calcium, ultimately determining an increase in PTH secretion [31] . In addition to parathyroid tissue, the receptor is also expressed in the regions of the kidney involved in the regulation of Ca and magnesium (Mg) reabsorption [32] and in many different tissues throughout the body [33] . Conversely, calcitriol increases both intestinal Ca and Pi absorption and renal Pi reabsorption [34, 35] . In addition, PTHrelated peptide (PTHrP), first discovered as the major cause of the humoral hypercalcemia of malignancy [36] , is evolutionarily and functionally related to PTH and also functions as mineral metabolism regulator. It is expressed by a variety of fetal and adult tissues, having a prominent role in the regulation of endochondral bone formation [37] and in the organogenesis of several epithelial tissues (i.e., skin, mammary gland, teeth) [38] . The most recently identified calciophosphotropic hormones are the phosphatonins [29, 31] (b). The term phosphatonins is used to describe factors responsible for the inhibition of Pi renal reabsorption by cotransporter and for the modulation of the 1-alphahydroxylase levels [29] . These molecules include FGF23, PHEX, matrix extracellular phosphoglycoprotein (MEPE), secreted frizzled related protein 4 (sFRP4), and fibroblast growth factor 7 (FGF7) [36, 37, 76] . Most of the studies indicate FGF23 as the most important phosphatonin. Functional in vitro studies show that FGF23 activity is regulated by proteases and its specific receptors [38] . Mature FGF23 is degraded to two small fragments by the furin family proteases [39] . Moreover, the tissue-specific activity of FGF23 can be explained on the basis of the need for the presence of both fibroblast growth factor receptors (FGFRs) and Klotho (KL), a coreceptor for FGF23 that increases the affinity of FGF23 for FGFRs [40] . In bone tissue, Ca and Pi interact with cells of the bone-forming lineage and with the extracellular matrix proteins to control the osteoid mineralization [32] , while deposition of minerals in soft tissues is prevented through less wellunderstood factors [41] . The "bone" hormones measurable in serum
, and α-Klotho bone metabolism can be present (e.g., tumoral calcinosis) or maybe have not yet been assessed. For the majority of the listed disorders, biochemical features are not available, which underlines the need for a better metabolic characterization. Determination of biomarkers related to mineral metabolism as well as systematic assessment of BMD and quality of bone by improved diagnostic tools is, therefore, needed. However, these investigations are not disease-specific and are not commonly employed, unless patients are evaluated in referral centers by bone specialists with expertise in rare skeletal disorders. In selected cases, bone biopsy and in vitro assays can help to further refine the metabolic diagnosis. Many of the bone marker tests, not available at the time of the first description of these diseases, are now routinely used, encouraging the biochemical/ metabolic characterization of disorders potentially characterized by metabolic fingerprints.
The metabolic framing of a rare skeletal disease is of paramount importance for therapeutics and can guide the clinician in the choice of the most appropriate pharmacological intervention. Indeed, the characterization of a rare bone disease for the bone-forming or bone-resorbing phenotype will lead to different therapeutic approaches (e.g., anabolics or antiresorptives). In this respect, an example is hypophosphatasia, the only rare bone disease, due to a specific metabolic enzymatic alteration, for which a targeted therapy (asfotase alpha) has recently been developed and for which an antiresorptive therapy is contraindicated. However, other rare genetic metabolic bone disorders are often treated with the available antiosteoporotic agents which are given without being included in their approved indications (off-label prescription). In such cases, knowledge of the bone metabolic and structural profile can help in choosing the most suitable therapy for a given clinical case. Fig. 8 Biochemical/instrumental exams and in vitro tests for characterizing metabolic bone diseases. Measurements of biochemical indexes and hormones regulating mineral homeostasis can help in confirming or excluding systemic bone metabolic disorders. The assessment of bone turnover is important in order to plan further therapeutic approaches. Bone quantity and quality appraisal and prevalent vertebral fracture assessment may help to refine the metabolic framing of the disease, manifesting with an otherwise evident bone phenotype, and is crucial in the follow-up of the treated patient. Bone biopsy is critical in selected cases for the identification and for differential diagnosis. In vitro assays can be useful to identify supposed functional abnormalities of bone cells and/or matrix proteins (e.g., in collagenrelated disorders) Table 4 #300910 300131
PLS3
Xq23
See Table 4 OI with calcification in interosseous membranes and/or hypertrophic callus (OI type V) #610967 614757 IFITM5 11p15.5
See Table 4 Unclassified OI-like disorders:
Disorders with a phenotype similar to OI
• Osteoporosis-pseudoglioma syndrome (OPPG)
See Table 4 • NR not reported Table 6 Hyperphosphatasia with mental retardation syndrome 2 (HPMRS2)
See Table 6 Hyperphosphatasia with mental retardation syndrome 3 (HPMRS3)
See Table 6 Hyperphosphatasia with mental retardation syndrome 4 (HPMRS4) #615716 611801 PGAP3 17q12 See Table 6 Endocrine disorder resulting from a persistent hypercalcemia supported by an inadequate secretion of PTH; rarely it occurs in familial syndromes.
Systemic signs: renal (polyuria, hypercalciuria, nephrolithiasis) skeletal, neuromuscular (myopathy, chondrocalcinosis, arthritis), central nervous system (fatigue, cognitive changes), gastrointestinal (peptic ulcer, pancreatitis), cardiovascular (hypertension, reduction QT interval), bone-specific signs: osteoporosis with a reduction of bone mineral density mainly of the cortical bone, osteitis fibrosa cystica in severe cases (subperiostal resorption of the phalange, salt and pepper appearance of the skull, bone cysts, brown tumors of the long bones)
High Ca, low Pi, high Ur Pi, high Ur Ca, high PTH: 
Conclusions
In conclusion, with the present report, the IOF's SRD-WG provides for the first time a metabolic classification for RGMBDs. Surprisingly perhaps, bone remodeling phenotype is not known for all diseases of metabolic origin. However, knowledge of the metabolic pathway that characterizes a given disorder may help in the management of such patients. Indeed, for the majority of these disorders, disease-targeted therapies are still missing, restricting the choice between antiresorptive and anabolic agents in complicated syndromes, often in children. The metabolic profile may help in selecting the most appropriate pharmacological treatment in patients affected by RGMBDs. It is intended that this taxonomic paper will provide the core and the structural framework for the development of a web-based atlas for rare metabolic skeletal diseases by the International Osteoporosis Foundation with a detailed description and a guided diagnostic workup for each disease, leading to a targeted therapeutic approach on the basis of the available metabolic hallmarks and structural phenotypes.
